HIGH

Endo USA Recalls 1,041 Cartons of Everolimus 5mg Tablets Over IP-C Impurity (2025)

Endo USA, Inc. recalled 1,041 cartons of Everolimus 5mg tablets nationwide in the United States due to an impurity IP-C out of specification. The impurity IP-C is out of specification in the drug product. Patients and healthcare providers should stop using this product immediately and contact Endo USA or their healthcare provider for guidance.

Quick Facts at a Glance

Recall Date
September 5, 2025
Hazard Level
HIGH
Brands
Everolimus, Endo USA
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Failed Impurities/Degradation Specifications: Out of specification for impurity IP-C.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Endo USA, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Everolimus is an immunosuppressant medication used to prevent organ rejection in transplant patients. The 5mg tablet is prescription-only and distributed nationwide in the United States.

Why This Is Dangerous

The product contains an impurity (IP-C) out of specification. This could affect safety and efficacy for patients taking the recalled tablets.

Industry Context

This recall is not described as part of a broader industry pattern in the provided information.

Real-World Impact

Patients may need to switch medications under medical supervision. The recall could disrupt treatment plans and requires prompt action by providers and patients.

Practical Guidance

How to identify if yours is affected

  1. Check the label for NDC 49884-125-91
  2. Check Lot number 550172301 on the carton
  3. Verify Expiration date January 2026
  4. Confirm packaging: 28 tablets per carton (4 blister strips x 7)

Where to find product info

NDC, lot number, and expiration are on the carton and blister-pack labeling.

What timeline to expect

Recall processes for refunds/replacements typically follow internal company timelines and FDA guidance; exact duration not specified.

If the manufacturer is unresponsive

  • Document all communications with the manufacturer.
  • File a consumer complaint with the FDA if the company is unresponsive.
  • Consult your pharmacist or physician for guidance on alternative therapies.

How to prevent similar issues

  • Verify NDC numbers when dispensing or acquiring medications.
  • Be alert for recall notices from manufacturers and the FDA.
  • Ask pharmacists to confirm product lot details before dispensing high-risk drugs.

Documentation advice

Keep the recall notice, the product packaging, and any correspondence with Endo USA. Document batch/lot, NDC, and expiration for records.

Product Details

Cartons: 1,041. Product: Everolimus 5mg tablets. NDC: 49884-125-91. Lot: 550172301. Expiration: January 2026. Pack size: 28 tablets per carton (4 blister strips x 7 tablets). Rx only. Manufactured by: Par Pharmaceutical, Chestnut Ridge, NY 10977. Sold nationwide within the United States. Recall date: 2025-09-05. Status: ACTIVE.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 1,041 cartons recalled nationwide
  • Everolimus 5mg tablets, NDC 49884-125-91
  • Lot 550172301, Exp January 2026
  • Manufactured by Par Pharmaceutical, Chestnut Ridge, NY 10977
  • Rx only; distributed nationwide within the United States
  • Hazard level: HIGH; Impurity IP-C out of specification

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
OTHER

Product Details

Model Numbers
Lot #: 550172301
Exp. Date January 2026
UPC Codes
49884-119
49884-125
49884-127
+9 more
Affected States
ALL
Report Date
October 22, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more